佩普医药始终瞄准新药发展的动向，以临床需求为导向，通过高效率设计、合成以及药理筛选，寻找结构新药的候选化合物，目前多个靶点的化合物已进入成药性研究阶段。
| 项目名称 | 疾病 | 靶点 | 研发阶段 | 备注 |
专注于生物活性分子及其中间体的合成，工艺研究和优化，杂质及质量研究等。为全球医药企业和科研机构提供高品质小分子活性化合物。
| CAS号 | 货号 | 产品名称 | 结构式 |
| 2736508-60-2 | PP241018 | BGB-16673 | |
| 3043939-18-7 | PP241103 | BI-9787 | |
| 2766800-24-0 | PP241119 | ART26.12 | |
| 2768610-97-3 | PP241209 | MS41 | |
| 2413020-56-9 | PP241125 | BAY-593 | |
| 2564486-44-6 | PP241117 | BMS-986397 | |
| 1374524-68-1 | PP241102 | ME-344 | |
| 1352914-52-3 | PP241105 | CR-1-31-B | |
| 1589527-65-0 | PP240913 | KIRA6 | |
| 2370913-42-9 | PP240905 | Inixaciclib | |
| 2098191-53-6 | PP240916 | Zotatifin | |
| 2736508-94-2 | PP240918 | BTK-IN | |
| 2675452-91-0 | PP241018 | PFI-6 | |
| 2820336-67-0 | PP241012 | JBJ-09-063 | |
| 2714434-21-4 | PP231121 | IAG933 | |
| 1816331-66-4 | PP240703 | GSK864 | |
| 376348-65-1 | PP240905 | Maraviroc | |
| 1801787-56-3 | PP241008 | OICR-9429 | |
| 2834106-06-6 | PP240701 | LTGO-33 | |
| 446859-33-2 | PP240605 | RepSox | |
| 2519537-70-1 | PP240402 | HOIPIN-8 | |
| 2380321-51-5 | PP240617 | PF07220060 | |
| 2973395-71-8 | PP240227 | DHX9-IN-2 | |
| 2653994-08-0 | PP231226 | JDQ443 | |
| 1905481-40-4 | PP231106 | TK-129 | |
| 2563892-44-2 | PP230512 | IK-930 | |
| 1402608-02-9 | PP231229 | BAY1125976 | |
| 1416775-08-0 | PP231227 | Vevorisertib trihydrochloride | |
| 1216495-92-9 | PP231221 | Aceclofenac EP Impurity H | |
| 1360628-91-6 | PP231121 | M3541 | |
| 2146095-85-2 | PP240117 | SHIN1 | |
| 935666-88-9 | PP240108 | AZD1480 | |
| 300815-41-2 | PP240106 | RS102895 | |
| 215447-89-5 | PP231207 | Benazepril EP Impurity A HCl | |
| 1222998-36-8 | PP231011 | Torin 1 | |
| 300816-15-3 | PP230705 | RS504393 | |
| 160369-85-7 | PP230805 | 5-Bromo-4-chloro-3-indolyl-alpha-D-N-acetylneuraminic acid sodium salt | |
| 2832047-80-8 | PP230507 | RP-6685 | |
| 2750001-23-9 | PP230221 | AZD0095 | |
| 2639638-66-5 | PP230328 | BAY-069 | |
| 2756333-39-6 | PP220609 | AZD-9574 | |
| 74058-71-2 | PP230506 | Macamide B | |
| 2377491-54-6 | PP230524 | AGI-43192 | |
| 2863686-82-0 | PP230307 | SPEN-IN-1 | |
| 2016806-57-6 | PP221027 | AZ13705339 | |
| 2258608-78-3 | PP230220 | UCM-1306 | |
| 2186700-33-2 | PP230116 | Ervogastat | |
| 1933514-13-6 | PP230206 | sebetralstat | |
| 2156637-58-8 | PP221021 | 1-Hydroxy-3,6-bis[2-hydroxy-3-[methyl(phenylmethyl)amino]propoxy]-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one | |
| 64821-19-8 | PP220916 | VAR10300 | |
| 345952-44-5 | PP220809 | MM 11253 | |
| 2756818-39-8 | PP220809 | SB-216 | |
| 2762617-31-0 | PP220726 | YAP/TAZ inhibitor 2 | |
| 205240-63-7 | PP220602 | 2-Trifluoromethyl-6-chloro-5-pyridineboric acid | |
| 2071683-99-1 | PP220402 | NLG802 | |
| 2757405-31-3 | PP220508 | HDHODH-IN-8 | |
| 2761063-99-2 | PP220409 | ELOVL1-IN-3 | |
| 457657-34-0 | PP220412 | PA 452 | |
| 1845777-61-8 | PP220307 | Gilmelisib | |
| 796854-35-8 | PP220408 | WAY-204688 | |
| 903895-98-7 | PP220830 | TC-FPR 43 | |
| 20287-37-0 | PP220413 | Fenquizone | |
| 2244987-03-7 | PP220407 | CDK12-IN-2 | |
| 2185857-97-8 | PP220203 | PF-06873600 | |
| 2229711-68-4 | PP211201 | ARV471 | |
| 1430472-11-9 | PP211106 | ||
| 1639892-90-2 | PP211105 | ||
| 2170137-61-6 | PP210928 | GSK3685032 | |
| 104421-21-8 | PP210926 | Dup-721 | |
| 1330782-76-7 | PP210922 | TAK-931 | |
| 714240-31-0 | PP210824 | NCGC00029283 | |
| 2201056-66-6 | PP210927 | AG-270 | |
| 899937-47-4 | PP210924 | WRX606 | |
| 261925-02-4 | PP210713 | 3-((methylsulfonyl)methyl)aniline | |
| 1042433-41-9 | PP210714 | GSK-1520489A | |
| 7509-12-8 | PP210908 | 4-oxo-1,4-dihydroquinoline-3-carbaldehyde | |
| 2197052-44-9 | PP210908 | 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine.2HCl | |
| 71879-53-3 | PP210806 | ||
| 745066-18-6 | PP210604 | 2-(piperazin-1-yl)-5-(trifluoromethyl)pyrimidine |
